Parvoviruses and bone marrow failure

Area of Science:

• Virology
• Hematology

Background:

• Parvovirus B19 is the sole known human pathogenic parvovirus.
• It exhibits high tropism for human bone marrow, specifically targeting erythroid progenitor cells.
• This tropism is mediated by the globoside (blood group P antigen) receptor.

Purpose of the Study:

• To elucidate the erythroid tropism of Parvovirus B19.
• To understand the clinical manifestations of Parvovirus B19 infection.
• To review diagnostic and therapeutic approaches for Parvovirus B19.

Main Methods:

• Analysis of Parvovirus B19's cellular receptor.
• Review of clinical cases presenting with Parvovirus B19 infection.
• Evaluation of diagnostic methods including bone marrow examination and virological studies.
• Assessment of treatment efficacy, particularly immunoglobulin therapy.

Main Results:

• Parvovirus B19 infection causes transient aplastic crisis in individuals with hemolytic disorders.
• Persistent infection in immunocompromised patients can lead to pure red cell aplasia and chronic anemia.
• In utero infection may result in fetal death, hydrops fetalis, or congenital anemia.
• Immunoglobulin treatment rapidly resolves anemia in persistent B19 infections.

Conclusions:

• Parvovirus B19's erythroid tropism is determined by globoside receptor distribution.
• The virus poses significant risks, including aplastic crisis, chronic anemia, and fetal complications.
• Diagnosis relies on bone marrow and virological assessments.
• Immunoglobulin therapy is an effective treatment for persistent Parvovirus B19 infection.